MiRXES
MiRXES is a Singapore-headquartered biotechnology company.
Mirxes reports $95.4m net loss ahead of IPO
Mirxes reports $95.4m net loss ahead of IPO
Costs of R&D and administrative activities widened last year’s losses.
Read Here
Advertise
Sign Up
Commentary
Why the impact of AI is being underestimated and how it will transform business productivity in Hong Kong
The strategic decarbonisation model for Hong Kong real estate
The survival playbook for the CEO amidst geopolitical conflicts
The succession shift: Redesigning wealth structures for the next generation